Importance of Treatment Duration: Unmasking Barriers and Discovering the Reasons for Undertreatment of Anti-VEGF Agents in Neovascular Age-Related Macular Degeneration
Bianka Sobolewska,1 Muhammed Sabsabi,1 Focke Ziemssen2,3 1Center for Ophthalmology, Eberhard- Karls University, Tuebingen, Germany; 2University Eye Hospital, Center for Ophthalmology, University of Tübingen, Tuebingen, Germany; 3Department of Ophthalmology, University Hospital Leipzig, Leipzig, Germ...
Guardado en:
| Autores principales: | Sobolewska B, Sabsabi M, Ziemssen F |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6a79620c85de424a9217c19be01b832c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou SA, et al.
Publicado: (2017) -
The burden of neovascular age-related macular degeneration: a patient’s perspective
por: Spooner KL, et al.
Publicado: (2018) -
Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
por: Spooner K, et al.
Publicado: (2017) -
Specific Autoantibodies in Neovascular Age-Related Macular Degeneration: Evaluation of Morphological and Functional Progression over Five Years
por: Michelle Prasuhn, et al.
Publicado: (2021) -
Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration – Current Perspectives
por: Phan LT, et al.
Publicado: (2021)